Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:BLTENASDAQ:HRMYNASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$6.92-0.4%$7.27$5.90▼$34.11$505.10M2.211.38 million shs1.99 million shsBLTEBelite Bio$64.22-1.6%$60.93$43.70▼$86.53$2.04B-1.4448,303 shs20,404 shsHRMYHarmony Biosciences$35.03-0.4%$31.70$26.47▼$41.61$2.01B0.87611,965 shs502,597 shsNAMSNewAmsterdam Pharma$19.51+0.6%$17.75$14.06▼$27.29$2.18B-0.03657,960 shs1.08 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.43%-7.73%-0.43%-62.14%-75.22%BLTEBelite Bio-1.62%-2.16%+4.02%+1.63%+31.90%HRMYHarmony Biosciences-0.37%+2.88%+9.30%+4.04%+17.24%NAMSNewAmsterdam Pharma+0.62%+10.66%+2.68%-18.03%+1.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.3328 of 5 stars4.32.00.00.01.82.51.3BLTEBelite Bio2.144 of 5 stars3.53.00.00.01.80.80.6HRMYHarmony Biosciences4.9418 of 5 stars4.64.00.00.03.43.34.4NAMSNewAmsterdam Pharma2.6737 of 5 stars3.51.00.00.02.75.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29193.20% UpsideBLTEBelite Bio 3.00Buy$96.6750.52% UpsideHRMYHarmony Biosciences 3.11Buy$53.0051.30% UpsideNAMSNewAmsterdam Pharma 3.00Buy$42.86119.67% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, NAMS, BLTE, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.18N/AN/A$8.17 per share0.85BLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/AHRMYHarmony Biosciences$744.85M2.70$2.62 per share13.38$7.97 per share4.40NAMSNewAmsterdam Pharma$47.14M46.47N/AN/A$3.50 per share5.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)BLTEBelite Bio-$31.63M-$1.36N/AN/AN/AN/A-31.94%-30.73%8/8/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.6216.6011.260.4717.98%23.16%14.24%8/5/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)Latest ARVN, NAMS, BLTE, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64BLTEBelite BioN/A30.7330.73HRMYHarmony Biosciences0.283.243.20NAMSNewAmsterdam PharmaN/A10.6110.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%BLTEBelite Bio0.53%HRMYHarmony Biosciences86.23%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%BLTEBelite Bio13.29%HRMYHarmony Biosciences23.60%NAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million65.18 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableHRMYHarmony Biosciences20057.42 million39.47 millionOptionableNAMSNewAmsterdam Pharma4112.27 million74.37 millionOptionableARVN, NAMS, BLTE, and HRMY HeadlinesRecent News About These CompaniesNewAmsterdam Pharma to Host R&D Day on June 11, 2025June 5 at 8:00 AM | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at Cantor FitzgeraldJune 5 at 3:51 AM | americanbankingnews.comShort Interest in NewAmsterdam Pharma (NASDAQ:NAMS) Grows By 23.6%June 4 at 6:08 PM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 7.2% - Here's WhyJune 4 at 2:36 PM | marketbeat.comCantor Fitzgerald Initiates Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)June 4 at 8:16 AM | marketbeat.comNewAmsterdam Pharma (NAMS) Receives Overweight Rating from Cantor Fitzgerald | NAMS Stock NewsJune 4 at 6:27 AM | gurufocus.comBuy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential HighlightedJune 3 at 8:33 PM | tipranks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.52 Million Stake in NewAmsterdam Pharma (NASDAQ:NAMS)June 2, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Holdings Trimmed by Two Sigma Investments LPJune 1, 2025 | marketbeat.comNorthern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)June 1, 2025 | marketbeat.comWellington Management Group LLP Acquires 2,222,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)May 31, 2025 | marketbeat.com28,041 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Acquired by Voloridge Investment Management LLCMay 31, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Holdings Trimmed by Two Sigma Advisers LPMay 31, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street ZenMay 31, 2025 | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street ZenMay 31, 2025 | marketbeat.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.00May 28, 2025 | americanbankingnews.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneMay 27, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by Millennium Management LLCMay 26, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of "Buy" by AnalystsMay 26, 2025 | marketbeat.comNewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular marketMay 24, 2025 | investing.com35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial MarketsMay 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, NAMS, BLTE, and HRMY Company DescriptionsArvinas NASDAQ:ARVN$6.92 -0.03 (-0.43%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$7.02 +0.09 (+1.37%) As of 08:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Belite Bio NASDAQ:BLTE$64.22 -1.06 (-1.62%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$64.22 +0.00 (+0.01%) As of 06/5/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Harmony Biosciences NASDAQ:HRMY$35.03 -0.13 (-0.37%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$35.01 -0.02 (-0.07%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.NewAmsterdam Pharma NASDAQ:NAMS$19.51 +0.12 (+0.62%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$19.52 +0.00 (+0.03%) As of 06/5/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
